



# Financial tear sheet

## Corporate Profile

2015 was a pivotal year for Baxter: In July we executed the spinoff of our BioScience business. The corporate separation created value for investors and resulted in a Baxter portfolio focused solely on the Hospital Products and Renal technologies central to our core identity. Today we are collaborating around the world to shape a leaner, more efficient company, positioned to deliver on our mission and succeed on behalf of all our stakeholders well into the future.

## Stock Information

BAX (BAX)	
<b>Exchange</b>	NYSE (US Dollar)
<b>Price</b>	\$59.18
<b>Change (%)</b>	▲ 0.84 (1.44%)
<b>Volume</b>	1,145,479
<b>52 Week Low</b>	\$42.22
<b>Market Cap</b>	\$31,717,656,111
<b>Rolling EPS</b>	3.36
<b>PE Ratio</b>	17.3859
<b>Shares Outstanding</b>	543,669,114
Data as of 05/25/2017 1:00 PM ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

## Latest News

DATE	TITLE
05/23/17	Baxter Presents Data at ISPOR Annual Meeting with Focus on Helping Hospitals Improve Patient Care
05/19/17	Commonwealth Fund President, David Blumenthal, MD, MPP, Named 2017 Recipient of the William B. Graham Prize for Health Services Research
05/18/17	Baxter to Present at the Goldman Sachs 38th Annual Healthcare Conference

## Recent & Upcoming Events

DATE	TITLE
04/26/2017 7:30 AM CT	Q1 2017 Baxter International Inc. Earnings Conference Call
05/02/2017 9:00 AM CT	Baxter's Annual Meeting of Stockholders
05/16/2017 10:00 AM PT	Bank of America Merrill Lynch Healthcare Conference
	<b>Location</b> Las Vegas

## SEC Filings

FILING DATE	FORM
05/24/17	4
05/22/17	424B2
05/19/17	FWP
05/19/17	424B5

## Primary IR Contact

Clare Trachtman  
Baxter International Inc.  
**Phone:** 224-948-3085